1976
DOI: 10.1002/jps.2600650310
|View full text |Cite
|
Sign up to set email alerts
|

Dissolution Rates of High Energy Sulfathiazole‐Povidone Coprecipitates II: Characterization of Form of Drug Controlling Its Dissolution Rate via Solubility Studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
47
0
1

Year Published

2004
2004
2015
2015

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 126 publications
(48 citation statements)
references
References 3 publications
0
47
0
1
Order By: Relevance
“…According to this analysis, the dissolution rate can be enhanced by increasing the effective surface area available for dissolution (i.e., decreasing the particle size of the solids) or by improving the kinetic solubility of the drug under physiologically relevant conditions (i.e., employing ASDs). In early studies of amorphous pharmaceuticals, pioneering researchers such as Goldberg et al (5,6), Simonelli et al (7,8), and Chiou et al (9) all conducted their dissolution experiments under sink conditions and thereby emphasized the importance of a high dissolution rate of amorphous drugs from solid dispersions (e.g., sulfathiazole-polyvinylpyrrolidone PVP, griseofulvinpolyethylene glycol PEG) or eutectic mixtures (e.g., acetaminophen-urea, griseofulvin-succinic acid) as an essential criterion for assessing the solubility improvement. Consequently, the concept of enhancing dissolution rates of amorphous pharmaceuticals by incorporating rapidly dissolving ASD carriers has been adopted and propagated to succeeding generations of formulation design for orally administered poorly water-soluble drugs.…”
Section: Introductionmentioning
confidence: 99%
“…According to this analysis, the dissolution rate can be enhanced by increasing the effective surface area available for dissolution (i.e., decreasing the particle size of the solids) or by improving the kinetic solubility of the drug under physiologically relevant conditions (i.e., employing ASDs). In early studies of amorphous pharmaceuticals, pioneering researchers such as Goldberg et al (5,6), Simonelli et al (7,8), and Chiou et al (9) all conducted their dissolution experiments under sink conditions and thereby emphasized the importance of a high dissolution rate of amorphous drugs from solid dispersions (e.g., sulfathiazole-polyvinylpyrrolidone PVP, griseofulvinpolyethylene glycol PEG) or eutectic mixtures (e.g., acetaminophen-urea, griseofulvin-succinic acid) as an essential criterion for assessing the solubility improvement. Consequently, the concept of enhancing dissolution rates of amorphous pharmaceuticals by incorporating rapidly dissolving ASD carriers has been adopted and propagated to succeeding generations of formulation design for orally administered poorly water-soluble drugs.…”
Section: Introductionmentioning
confidence: 99%
“…The main reason for the increased dissolution of the drug in presence of PVP might be due to crystal growth inhibition. It has been shown that PVP may serve to inhibit precipitation of drug from the supersaturated solution (Simonelli et al, 1976;Usui et al, 1997). Another reason for the increased dissolution of drug in presence of PVP could be the increased surface area of the drug exposed to the dissolution medium as a result of the adsorption on carrier.…”
Section: Solubility and Dissolution Studiesmentioning
confidence: 99%
“…However, the release rates of the two forms in pH 6.8 medium were almost the same. The release rate was obtained by plotting the Higuchi equation: (2) where Q is the percentage of release of the drug, t is the release time, and K is the apparent release rate constant. In addition, the 70% release time (T 70 ) was compared to the latter half of the release.…”
Section: Resultsmentioning
confidence: 99%